Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Predicted to be involved in cilium assembly and intraciliary retrograde transport. Located in centriole and cilium. Part of intraciliary transport particle A. Is expressed in several structures, including cardiovascular system; endocrine gland; genitourinary system; mesenteric lymph node; and nervous system. Human ortholog(s) of this gene implicated in cranioectodermal dysplasia 3; retinitis pigmentosa 81; and short-rib thoracic dysplasia 18 with polydactyly. Orthologous to human IFT43 (intraflagellar transport 43). [provided by Alliance of Genome Resources, Feb 2025]